Treatment Study for Patients with Prostate Cancer

Clinical Trial Title

Phase II-III trial of adjuvant radiotherapy following radical prostatectomy with or without adjuvant docetaxel.

Contact Information

Rush Cancer Center Clinical Trials Office

Clinical Trial Protocol Description:

This randomized phase II/III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed by surgery. Androgen can cause the growth of prostate cells. Antihormone therapy may lessen the amount of androgen made by the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving antiandrogen therapy and radiation therapy with or without docetaxel after surgery may kill any remaining tumor cells.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have primary treatment with radical prostatectomy.
  • Have any type of radical prostatectomy, including retropubic, perineal, laparoscopic or robotically assisted.
  • Have baseline testosterone level obtained post prostatectomy.
  • May participate if you have prior ablative treatment for treatment of benign prostatic hypertrophy or focal high-intensity focused ultrasound therapy (HIFU) prior to prostatectomy.

This is a partial list of elgibility requirements.

Study Details

Clinical Trial Investigator

Dian Wang, MD, PhD

Contact Information

Rush Cancer Center Clinical Trials Office


Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more